Relmada Therapeutics (RLMD) Research & Development (2014 - 2026)
Relmada Therapeutics (RLMD) reported Research & Development of $8.1 million for Q1 2026, down 32.33% year-over-year from $12.0 million in Q1 2025, and little changed on a QoQ basis from $8.1 million in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Research & Development data on file, last reported at $8.1 million in Q1 2026.
- Quarterly Research & Development fell 32.33% year-over-year to $8.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23.0 million (down 48.65% YoY) and the FY2025 annual result came in at $26.9 million, down 41.79% from the prior year.
- Research & Development steadied at $8.1 million in Q1 2026 per RLMD's latest filing, from $8.1 million in the prior quarter.
- Across five years, Research & Development topped out at $30.9 million in Q2 2022 and bottomed at $2.8 million in Q2 2025.
- The 5-year median for Research & Development is $12.0 million (2025), against an average of $14.7 million.
- The widest annual swing landed in 2022, when Research & Development surged 78.38%; it then tumbled 73.7% in 2025.
- Tracing RLMD's Research & Development over 5 years: stood at $26.9 million in 2022, then tumbled by 45.1% to $14.8 million in 2023, then retreated by 25.43% to $11.0 million in 2024, then slipped by 26.61% to $8.1 million in 2025, then increased by 0.19% to $8.1 million in 2026.
- Per Business Quant, the three latest RLMD Research & Development figures stand at $8.1 million (Q1 2026), $8.1 million (Q4 2025), and $4.0 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | 8.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.09 Mn |
| Dec 31, 2025 | 8.07 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2025 | 11.95 Mn |
| Dec 31, 2024 | 11.00 Mn |
| Sep 30, 2024 | 11.15 Mn |
| Jun 30, 2024 | 10.72 Mn |
| Mar 31, 2024 | 13.31 Mn |
| Dec 31, 2023 | 14.75 Mn |
| Sep 30, 2023 | 10.45 Mn |
| Jun 30, 2023 | 13.74 Mn |
| Mar 31, 2023 | 15.86 Mn |
| Dec 31, 2022 | 26.87 Mn |
| Sep 30, 2022 | 30.53 Mn |
| Jun 30, 2022 | 30.91 Mn |
| Mar 31, 2022 | 25.01 Mn |
| Dec 31, 2021 | 25.27 Mn |
| Sep 30, 2021 | 33.99 Mn |
| Jun 30, 2021 | 17.33 Mn |
| Mar 31, 2021 | 14.02 Mn |
| Dec 31, 2020 | 14.90 Mn |
| Sep 30, 2020 | 11.24 Mn |
| Jun 30, 2020 | 5.32 Mn |
| Mar 31, 2020 | 4.51 Mn |
| Dec 31, 2019 | 3.51 Mn |
| Sep 30, 2019 | 1.89 Mn |
| Jun 30, 2019 | 3.07 Mn |
| Mar 31, 2019 | 1.28 Mn |
| Dec 31, 2018 | 1.26 Mn |
| Sep 30, 2018 | 1.42 Mn |
| Mar 31, 2018 | 1.67 Mn |
| Dec 31, 2017 | 150,720.00 |
| Sep 30, 2017 | 165,750.00 |
| Jun 30, 2017 | 184,550.00 |
| Mar 31, 2017 | 490,691.00 |
| Dec 31, 2016 | 254,105.00 |
| Sep 30, 2016 | 364,152.00 |
| Jun 30, 2016 | 613,749.00 |
| Mar 31, 2016 | 609,121.00 |
| Dec 31, 2015 | 2.12 Mn |
| Sep 30, 2015 | 2.87 Mn |
| Jun 30, 2015 | 2.86 Mn |
| Mar 31, 2015 | 2.27 Mn |
| Dec 31, 2014 | 2.09 Mn |
| Sep 30, 2014 | 718,974.00 |
| Jun 30, 2014 | 839,959.00 |
| Mar 31, 2014 | -215,793.00 |